WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H413860
CAS#: 272786-64-8
Description: Unifiram is a nootropic agent. It increases acetylcholine (ACh) release in the rat cerebral cortex in vivo and induces a long-lasting increase in the amplitude of field excitatory postsynaptic potentials (fEPSPs) in the rat hippocampal CA1 region (EC50 = 27 nM). It does not bind to serotonin (5-HT), dopamine, muscarinic, nicotinic, adrenergic, glutamate, histamine, opioid, or GABA receptors at 1 µM. Unifiram (0.1 mg/kg) improves memory in non-memory-impaired rats in a social learning test. It also prevents memory deficits induced by the anticholinergic agent scopolamine, nicotinic receptor antagonist mecamylamine, GABAB receptor agonist baclofen, or α2-adrenergic receptor agonist clonidine in the passive avoidance test in mice when administered at a dose of 0.01 mg/kg and prevents memory deficits induced by the AMPA/kainate glutamate receptor antagonist NBQX at 0.1 mg/kg.
Hodoodo Cat#: H413860
Name: Unifiram
CAS#: 272786-64-8
Chemical Formula: C13H15FN2O3S
Exact Mass: 298.08
Molecular Weight: 298.330
Elemental Analysis: C, 52.34; H, 5.07; F, 6.37; N, 9.39; O, 16.09; S, 10.75
Synonym: Unifiram; DM232; DM 232; DM-232
IUPAC/Chemical Name: 2-((4-Fluorophenyl)sulfonyl)hexahydropyrrolo(1,2-a)pyrazin-6(2H)-one
InChi Key: SNRTZFZAFBIBJP-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H15FN2O3S/c14-10-1-4-12(5-2-10)20(18,19)15-7-8-16-11(9-15)3-6-13(16)17/h1-2,4-5,11H,3,6-9H2
SMILES Code: O=C1CCC2CN(S(=O)(C3=CC=C(F)C=C3)=O)CCN21
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMF | 30.0 | 100.56 | |
DMSO | 30.0 | 100.56 | |
DMSO:PBS (pH 7.2) (1:4) | 0.2 | 67.04 | |
Ethanol | 1.0 | 3.35 |
The following data is based on the product molecular weight 298.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Gualtieri F. Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings. J Enzyme Inhib Med Chem. 2016;31(2):187-94. doi: 10.3109/14756366.2015.1021252. Epub 2015 Apr 1. PMID: 25831025.
2: Guandalini L, Martino MV, Di Cesare Mannelli L, Bartolucci G, Melani F, Malik R, Dei S, Floriddia E, Manetti D, Orlandi F, Teodori E, Ghelardini C, Romanelli MN. Substituted piperazines as nootropic agents: 2- or 3-phenyl derivatives structurally related to the cognition-enhancer DM235. Bioorg Med Chem Lett. 2015 Apr 15;25(8):1700-1704. doi: 10.1016/j.bmcl.2015.03.009. Epub 2015 Mar 12. PMID: 25813160.
3: Martini E, Norcini M, Ghelardini C, Manetti D, Dei S, Guandalini L, Melchiorre M, Pagella S, Scapecchi S, Teodori E, Romanelli MN. Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators. Bioorg Med Chem. 2008 Dec 1;16(23):10034-42. doi: 10.1016/j.bmc.2008.10.017. Epub 2008 Oct 11. PMID: 18954993.
4: Romanelli MN, Galeotti N, Ghelardini C, Manetti D, Martini E, Gualtieri F. Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers. CNS Drug Rev. 2006 Spring;12(1):39-52. doi: 10.1111/j.1527-3458.2006.00039.x. PMID: 16834757; PMCID: PMC6741768.
5: Martini E, Ghelardini C, Bertucci C, Dei S, Gualtieri F, Guandalini L, Manetti D, Scapecchi S, Teodori E, Romanelli MN. Enantioselective synthesis and preliminary pharmacological evaluation of the enantiomers of unifiram (DM232), a potent cognition-enhancing agent. Med Chem. 2005 Sep;1(5):473-80. doi: 10.2174/1573406054864142. PMID: 16787332.
6: Scapecchi S, Martini E, Manetti D, Ghelardini C, Martelli C, Dei S, Galeotti N, Guandalini L, Novella Romanelli M, Teodori E. Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs. Bioorg Med Chem. 2004 Jan 2;12(1):71-85. doi: 10.1016/j.bmc.2003.10.025. PMID: 14697772.
7: Galeotti N, Ghelardini C, Pittaluga A, Pugliese AM, Bartolini A, Manetti D, Romanelli MN, Gualtieri F. AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram). Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):538-45. doi: 10.1007/s00210-003-0812-6. Epub 2003 Nov 5. PMID: 14600801.
8: Bronder E, Klimpel A. Unused drugs returned to the pharmacy--new data. Int J Clin Pharmacol Ther. 2001 Nov;39(11):480-3. PMID: 11727967.
9: Manetti D, Ghelardini C, Bartolini A, Bellucci C, Dei S, Galeotti N, Gualtieri F, Romanelli MN, Scapecchi S, Teodori E. Design, synthesis, and preliminary pharmacological evaluation of 1, 4-diazabicyclo[4.3.0]nonan-9-ones as a new class of highly potent nootropic agents. J Med Chem. 2000 May 18;43(10):1969-74. doi: 10.1021/jm991170t. PMID: 10821709.